HEMACARE ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of HEMA and Encourages Investors to Contact the Firm

NEW YORK, Dec. 16, 2019 /PRNewswire/ -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder law firm, has launched an investigation into whether the board members of HemaCare Corporation (Other OTC: HEMA) breached their fiduciary duties or violated the federal securities laws in connection with the company's proposed sale to Charles River Laboratories International, Inc.

Click here to learn more and participate in the action.

On December 16, 2019, HemaCare announced that it had signed an agreement to be acquired by Charles River for $25.40 per share in cash, or a total of approximately $380 million. The deal is scheduled to close in the first quarter of 2020.

Bragar Eagel & Squire is concerned that HemaCare's board of directors oversaw an unfair process and ultimately agreed to an inadequate deal price. Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for HemaCare stockholders.

If you own shares of HemaCare and are concerned about the proposed merger, or you're interested in learning more about the investigation or your legal rights and remedies, please contact Brandon Walker or Alexandra Raymond by email at [email protected] or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.

About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com.  Attorney advertising.  Prior results do not guarantee similar outcomes. 

SOURCE Bragar Eagel & Squire, P.C.